news
Collaboration to identify novel COVID-19 drug targets announced
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
List view / Grid view
Drug targets
news
Antibodies developed from llama show promise in fighting COVID-19
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
article
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news
AI platform developed to rapidly identify treatment regimens for infections, including COVID-19
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
news
NIAID releases strategic plan, outlining COVID-19 research priorities
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
article
Cytokine storms: a major killer in patients with severe COVID-19 infection
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
news
Cell types enabling initial COVID-19 infection identified by researchers
An international group of researchers has revealed that goblet and ciliated cells in the nose have high levels of the entry proteins for the SARS-CoV-2 coronavirus.
news
Hyperferritinaemia could be causing severe COVID-19
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
article
Natural peptides versus COVID-19
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
article
Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
news
Fundamental molecular research underpins our ability to combat COVD-19, says article
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
news
Lead SARS-CoV-2 inhibitor compound identified by researchers to treat COVID-19
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
news
Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
news
COVID-19 research indicates SARS-CoV-2 exploits immune defences to drive infection
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
news
Glycomimetics could prevent COVID-19 from infecting human cells
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
